ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
ASP Isotopes, through its subsidiary Quantum Leap Energy (QLE), has signed a non-binding memorandum of understanding with a large publicly traded U.S. energy company that operates nuclear power stations. The partner will evaluate options to support QLE’s plans to build advanced nuclear fuel cycle facilities in the United States.
The planned facilities would produce high assay low enriched uranium (HALEU) and low enriched uranium plus (LEU+), and provide uranium conversion and deconversion services. QLE aims to supply HALEU for advanced and small modular reactors and offer LEU+ to the existing reactor fleet to lengthen refueling intervals, cut costs, and increase power output.
QLE positions this initiative as a step toward strengthening the domestic nuclear fuel supply chain amid a federal ban on Russian uranium imports starting in 2028 and growing demand from next-generation reactor developers.
ASP Isotopes’ subsidiary Quantum Leap Energy appointed Nate Salpeter, Ph.D., as Chief Technology Officer. He is a recognized expert in fluid dynamics and energy technology optimization with more than 15 years of experience building computational, experimental, and engineering programs in advanced nuclear and thermal systems.
Dr. Salpeter previously held senior technical roles at TerraPower and Kairos Power, where he helped establish core fluid dynamics and modeling capabilities for next‑generation reactor projects. At Quantum Leap Energy, he will focus on optimizing in‑licensed and proprietary technologies, implementing rapid learning cycles, and leading methodical de‑risking to support commercialization of the company’s nuclear fuel and clean energy technologies.
The announcement highlights Quantum Leap Energy’s strategy as a development‑stage nuclear fuels company using Aerodynamic Separation Process and Quantum Enrichment technologies to address gaps in the nuclear fuel cycle for advanced reactors, small modular reactors, and fusion systems, supported by partnerships with leading industry and research organizations.
ASP Isotopes Inc. Executive Chairman Paul Elliot Mann reported an open-market sale of 162,153 shares of common stock at a weighted average price of $5.436 per share. According to the disclosure, these were “sell to cover” transactions under a Rule 10b5-1 trading plan to satisfy tax withholding on the quarterly vesting of a restricted stock award.
After these sales, Mann held 7,597,385 shares of ASP Isotopes common stock directly. The filing notes the shares were sold in multiple transactions at prices ranging from $5.10 to $5.57 per share.
Independent Trading Group Inc. (ASPI) filed a Form 144 reporting a proposed sale of 1,441,361 shares of common stock, listed as acquired as compensation under a restricted stock award on 04/14/2025.
The filing identifies the securities as common stock to be sold through NASDAQ and cites the 04/14/2025 grant date; cash‑flow treatment and exact planned sale timing are not shown in the excerpt.
ASP Isotopes’ subsidiary Quantum Leap Energy has deepened its collaboration with the South African Nuclear Energy Corporation (Necsa) by signing a Pre-Implementation Services Contract for a planned High Assay Low Enriched Uranium (HALEU) enrichment facility at Necsa’s Pelindaba site.
Under the agreement, Necsa will provide facilities, infrastructure, utilities and services to support the siting, design, construction, commissioning and operation of the enrichment facility. A joint committee with representatives from both parties will oversee implementation, aiming to bring QLE’s HALEU production capabilities to market readiness.
The partnership combines QLE’s proprietary Aerodynamic Separation Process and Quantum Enrichment technologies with Necsa’s established nuclear infrastructure and global networks. It targets growing demand for HALEU, a key fuel for small modular and other advanced reactors, as advanced nuclear projects scale to serve data centers and industrial electrification.
ASP Isotopes Inc., through its wholly owned subsidiary Quantum Leap Energy (QLE), has created a Strategic Advisory Board to support its plans in the nuclear fuel sector and appointed two initial members, nuclear engineering academic leader Mary Lou Dunzik-Gougar and advanced materials executive Kevin Kramer.
The board is expected to guide QLE as it develops proprietary technologies to address inefficiencies, environmental concerns, and supply chain vulnerabilities across the nuclear fuel cycle, including front-end enrichment activities and back-end waste treatment technologies for advanced reactors, fusion systems, and the existing nuclear fleet.
ASP Isotopes Inc. received an updated ownership report on its common stock from shareholder Paul E. Mann. Mann reported beneficial ownership of 7,759,538 shares of common stock, representing 7.0% of the class, as of 12/31/2025. He has sole voting and dispositive power over all reported shares, with no shared voting or investment power disclosed.
ASP Isotopes, through its wholly owned subsidiary Quantum Leap Energy (QLE), plans to establish QLE’s new global corporate headquarters in Austin, Texas. The move is intended to strengthen its Texas presence and position the development-stage nuclear fuels company closer to its U.S. customer base.
QLE also plans a significant operational presence in Texas, working with Fermi America under an existing memorandum of understanding to pursue a joint venture for a high-assay low-enriched uranium enrichment research and commercial production facility linked to Fermi America’s hypergrid campus in Amarillo. This would be developed alongside ASP Isotopes’ planned commercial facility for stable isotopes and advanced nuclear materials.
The announcement highlights Texas’ supportive regulatory and business environment for nuclear power and notes U.S. Department of Energy estimates that domestic demand for HALEU could reach 50 metric tons per year by 2035 and 500 metric tons per year by 2050, underscoring the potential market for advanced nuclear fuels.
BNP Paribas Asset Management UK Ltd has filed an amended Schedule 13G reporting beneficial ownership of 944,326 shares of ASP Isotopes Inc. common stock, representing 0.9% of the outstanding class as of December 31, 2025. The firm reports sole voting and dispositive power over all of these shares and confirms they are held in the ordinary course of business, not to change or influence control of ASP Isotopes.
ASP Isotopes Inc. agreed to invest in biotechnology company Opeongo by purchasing 4,356,918 shares of Opeongo’s Series Seed-1 Preferred Stock at an original purchase price of $2.2952 per share. The preferred stock is convertible into Opeongo common stock and carries anti-dilution protections, voting rights, and the ability for Series Seed-1 holders to elect a dedicated director while enough shares remain outstanding.
ASP Isotopes and other investors also received veto rights over certain major Opeongo corporate actions and contractual protections through investors’ rights, right of first refusal and co-sale, and voting agreements. Within thirty days after January 26, 2026, ASP Isotopes and Opeongo are obligated to negotiate a draft supply agreement giving ASP Isotopes a right of first offer for medical isotope supply tied to Opeongo’s future pharmaceutical products.